Emerald Mutual Fund Advisers Trust Purchases 638,568 Shares of Savara Inc. (NASDAQ:SVRA)

Emerald Mutual Fund Advisers Trust grew its stake in Savara Inc. (NASDAQ:SVRA - Free Report) by 46.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,014,456 shares of the company's stock after buying an additional 638,568 shares during the period. Emerald Mutual Fund Advisers Trust owned approximately 1.17% of Savara worth $5,580,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Cibc World Markets Corp purchased a new stake in Savara in the fourth quarter worth approximately $33,000. XTX Topco Ltd bought a new stake in shares of Savara in the 4th quarter worth approximately $34,000. Ameriprise Financial Inc. purchased a new stake in shares of Savara in the 4th quarter valued at $37,000. KLP Kapitalforvaltning AS bought a new position in shares of Savara during the 4th quarter valued at $41,000. Finally, Hsbc Holdings PLC purchased a new position in Savara in the 4th quarter worth $48,000. Institutional investors own 87.93% of the company's stock.

Insiders Place Their Bets

In other news, Director Richard J. Hawkins acquired 48,225 shares of the stock in a transaction on Friday, June 20th. The stock was acquired at an average price of $2.04 per share, with a total value of $98,379.00. Following the completion of the transaction, the director owned 115,466 shares of the company's stock, valued at $235,550.64. This represents a 71.72% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 5.33% of the company's stock.

Savara Trading Up 3.9%

Shares of NASDAQ SVRA traded up $0.09 during trading hours on Friday, hitting $2.39. The company's stock had a trading volume of 1,084,233 shares, compared to its average volume of 1,273,335. Savara Inc. has a 12 month low of $1.89 and a 12 month high of $5.11. The stock has a market cap of $413.09 million, a price-to-earnings ratio of -4.98 and a beta of 0.31. The company has a debt-to-equity ratio of 0.20, a quick ratio of 14.91 and a current ratio of 14.91. The business has a 50-day simple moving average of $2.49 and a 200-day simple moving average of $2.73.

Savara (NASDAQ:SVRA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, hitting analysts' consensus estimates of ($0.12). On average, analysts anticipate that Savara Inc. will post -0.45 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Evercore ISI cut their price target on shares of Savara from $3.00 to $2.00 and set an "in-line" rating for the company in a research report on Wednesday, May 28th. Wells Fargo & Company dropped their target price on Savara from $8.00 to $7.00 and set an "overweight" rating for the company in a report on Wednesday, May 28th. Guggenheim reaffirmed a "buy" rating and issued a $8.00 price target (down from $9.00) on shares of Savara in a research note on Wednesday, May 28th. Finally, HC Wainwright downgraded Savara from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $6.00 to $2.00 in a research report on Thursday, May 29th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Savara has an average rating of "Moderate Buy" and a consensus target price of $5.60.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.